Guggenheim Maintains Buy on Tenet Healthcare, Lowers Price Target to $252

Benzinga Newsdesk www.benzinga.com Neutral 47.6%

Neg 0% Neu 47.6% Pos 0%

Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:THC) with a Buy and lowers the price target from $283 to $252.